Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 10,000 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of Centessa Pharmaceuticals stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.04, for a total transaction of $170,400.00. Following the sale, the insider now owns 183,266 shares of the company's stock, valued at approximately $3,122,852.64. This represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Stock Up 2.1 %

CNTA traded up $0.36 on Thursday, hitting $17.26. 297,252 shares of the company were exchanged, compared to its average volume of 432,664. The firm has a 50-day moving average price of $16.71 and a two-hundred day moving average price of $13.81. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $6.65 and a twelve month high of $18.97. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -11.28 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC lifted its position in shares of Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company's stock worth $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. Farallon Capital Management LLC raised its stake in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company's stock valued at $18,024,000 after buying an additional 1,625,000 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Centessa Pharmaceuticals during the 3rd quarter worth about $20,698,000. Franklin Resources Inc. lifted its holdings in Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Finally, Driehaus Capital Management LLC boosted its position in shares of Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company's stock worth $18,891,000 after acquiring an additional 987,997 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on CNTA. BMO Capital Markets lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an "outperform" rating in a report on Monday, September 16th. Jefferies Financial Group boosted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, September 11th. Morgan Stanley upgraded Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a "buy" rating and a $33.00 target price for the company. Finally, Guggenheim increased their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.